RxDoctor Payments Data

Anitra Batie, MD

Family Medicine · Jasper, ALNPI 1316988199

Payments from drug & device makers

$1,545in general payments, 2019–2025

Across 47 payments — averaging $32.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$580
  • Novo Nordisk$446
  • AbbVie$172
  • Dexcom, Inc.$88
  • Astellas Pharma US Inc$65
  • GSK$50
  • plus $145 from 7 others

What the payments were for

  • Food & beverage$1,48096%
  • Education$654%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,545 in reported general payments places this provider in the 60th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$49,365
Medicare patients
191
Services billed
734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide290$371,386
EliquisApixaban143$136,051
MounjaroTirzepatide103$132,807
JardianceEmpagliflozin136$116,226
Trelegy ElliptaFluticasone/Umeclidin/Vilanter100$108,286
FarxigaDapagliflozin Propanediol61$56,901
LinzessLinaclotide71$46,495
XareltoRivaroxaban27$44,237
TrulicityDulaglutide32$43,027
JanuviaSitagliptin Phosphate54$42,192
Synjardy XrEmpagliflozin/Metformin Hcl39$29,701
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,037$25,390
XifaxanRifaximin15$22,543
Incruse ElliptaUmeclidinium Bromide38$21,122
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr36$20,487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$446$371,386290 claims
Lilly USA, LLCMounjaro, Trulicity$36$175,834135 claims
GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta, Breo Ellipta$50$169,619207 claims
PfizerEliquis$19$136,051143 claims
AstraZenecaFarxiga, Breztri Aerosphere$580$72,35974 claims
AbbVieLinzess$172$46,49571 claims
Astellas Pharma US IncMyrbetriq$65$16,63020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Jasper

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →